Revenue and margin performance show volatile top-line growth and a gross margin confined to 3.1% to 4.3%, with operating margin improving to 1.1% in the latest quarter on $753M of operating income, though net margin remains thin at 0.8%.
Cardinal Health, Inc. (CAH) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Jun'26 | Jun'25 | Jun'24 | Jun'23 | Jun'22 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jun'07 | Jun'06 | Jun'05 | Jun'04 | Jun'03 | Jun'02 | Jun'01 | Jun'00 | Jun'99 | Jun'98 | Jun'97 |
|---|
| Sales/Revenue | 257.75B | 254.25B | 222.58B | 226.83B | 204.98B | 181.33B | 162.47B | 152.92B | 145.53B | 136.81B | 129.98B | 121.55B | 102.53B | 91.08B | 101.09B | 107.55B | 102.64B | 98.5B | 95.99B | 87.41B | 86.85B | 79.66B | 72.67B | 64.52B | 56.73B | 51.14B | 47.95B | 38.35B | 25.11B | 21.08B | 18.39B |
| Revenue Growth % | 10% | 14.23% | -1.87% | 10.66% | 13.04% | 11.61% | 6.24% | 5.08% | 6.38% | 5.26% | 6.94% | 18.55% | 12.57% | -9.9% | -6.01% | 4.78% | 4.2% | 2.62% | 9.82% | 0.64% | 9.02% | 9.63% | 12.62% | 13.73% | 10.94% | 6.65% | 25.03% | 52.72% | 19.15% | 14.58% | 98.93% |
| Cost of Goods Sold | 247.7B | 244.47B | 214.41B | 219.41B | 198.1B | 174.84B | 155.69B | 146.05B | 138.7B | 129.63B | 123.43B | 115B | 96.82B | 85.92B | 96.17B | 103.01B | 98.48B | 94.72B | 92.24B | 83.63B | 81.61B | 74.85B | 68.21B | 59.88B | 52.25B | 47.09B | 44.34B | 35.25B | 22.25B | 18.6B | 16.16B |
| COGS % of Revenue | - | 96.16% | 96.33% | 96.73% | 96.65% | 96.42% | 95.83% | 95.51% | 95.3% | 94.75% | 94.97% | 94.62% | 94.43% | 94.33% | 95.13% | 95.78% | 95.95% | 96.16% | 96.1% | 95.68% | 93.96% | 93.96% | 93.86% | 92.8% | 92.1% | 92.09% | 92.47% | 91.93% | 88.61% | 88.24% | 87.88% |
| Gross Profit | 10.05B | 9.77B | 8.17B | 7.41B | 6.89B | 6.48B | 6.78B | 6.87B | 6.83B | 7.18B | 6.54B | 6.54B | 5.71B | 5.16B | 4.92B | 4.54B | 4.16B | 3.78B | 5.53B | 5.63B | 5.25B | 5.28B | 5.01B | 4.74B | 4.51B | 4.05B | 3.61B | 3.13B | 2.82B | 1.11B | 956.2M |
| Gross Margin % | 3.9% | 3.84% | 3.67% | 3.27% | 3.36% | 3.58% | 4.17% | 4.49% | 4.7% | 5.25% | 5.03% | 5.38% | 5.57% | 5.67% | 4.87% | 4.22% | 4.05% | 3.84% | 5.76% | 6.45% | 6.04% | 6.63% | 6.89% | 7.35% | 7.95% | 7.91% | 7.53% | 8.17% | 11.24% | 5.25% | 5.2% |
| Gross Profit Growth % | - | 19.66% | 10.17% | 7.62% | 6.25% | -4.34% | -1.31% | 0.5% | -4.83% | 9.73% | 0.02% | 14.55% | 10.68% | 4.88% | 8.37% | 9.11% | 10.09% | -31.59% | -1.91% | 7.41% | -0.67% | 5.48% | 5.6% | 5.13% | 11.46% | 12.03% | 15.28% | 11.02% | 155.19% | 15.65% | 27.87% |
| Operating Expenses | 7.35B | 7.16B | 5.89B | 6.17B | 6.12B | 7.09B | 6.31B | 10.97B | 4.77B | 7.05B | 4.42B | 4.08B | 3.55B | 3.28B | 3.92B | 2.75B | 2.65B | 2.47B | 2.46B | 2.38B | 3.87B | 2.97B | 2.68B | 2.31B | 2.3B | 2.21B | 2.12B | 1.82B | 1.82B | 1.62B | 1.51B |
| OpEx % of Revenue | - | 2.82% | 2.65% | 2.72% | 2.99% | 3.91% | 3.88% | 7.17% | 3.28% | 5.16% | 3.4% | 3.36% | 3.46% | 3.6% | 3.88% | 2.56% | 2.58% | 2.51% | 2.56% | 2.73% | 4.46% | 3.73% | 3.68% | 3.58% | 4.05% | 4.33% | 4.43% | 4.73% | 7.24% | 7.69% | 8.23% |
| Selling, General & Admin | 6.27B | 6.13B | 5.38B | 5B | 4.8B | 4.51B | 4.53B | 4.57B | 4.48B | 4.6B | 3.77B | 3.65B | 3.24B | 3.03B | 2.88B | 2.68B | 2.59B | 2.35B | 3.44B | 3.41B | 3.08B | 3.2B | 2.86B | 2.35B | 2.23B | 2.07B | 2B | 1.63B | 1.56B | 567.8M | 513.6M |
| SG&A % of Revenue | - | 2.41% | 2.42% | 2.2% | 2.34% | 2.49% | 2.79% | 2.99% | 3.08% | 3.36% | 2.9% | 3% | 3.16% | 3.32% | 2.84% | 2.49% | 2.53% | 2.38% | 3.58% | 3.91% | 3.55% | 4.02% | 3.94% | 3.64% | 3.93% | 4.06% | 4.17% | 4.24% | 6.23% | 2.69% | 2.79% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 3M | 1.03B | 511M | 1.17B | 1.32B | 2.58B | 1.77B | 6.39B | 294M | 2.46B | 649M | 436M | 311M | 248M | 1.05B | 72M | 120M | 77M | 126.6M | 44.1M | 789.3M | 86.3M | 179.8M | 43.7M | 48.9M | 138.6M | 173.8M | 106.2M | 238.2M | 218.4M | 209.1M |
| Operating Income | 2.7B | 2.61B | 2.27B | 1.24B | 752M | -607M | 472M | -4.1B | 2.06B | 126M | 2.12B | 2.46B | 2.16B | 1.89B | 996M | 1.79B | 1.51B | 1.31B | 1.29B | 1.39B | 1.37B | 1.84B | 1.78B | 2.33B | 2.19B | 1.83B | 1.49B | 1.28B | 1.04B | 858.1M | 715.7M |
| Operating Margin % | 1.05% | 1.03% | 1.02% | 0.55% | 0.37% | -0.33% | 0.29% | -2.68% | 1.42% | 0.09% | 1.63% | 2.02% | 2.11% | 2.07% | 0.99% | 1.67% | 1.47% | 1.33% | 1.34% | 1.59% | 1.58% | 2.32% | 2.45% | 3.61% | 3.85% | 3.59% | 3.1% | 3.34% | 4.15% | 4.07% | 3.89% |
| Operating Income Growth % | - | 14.86% | 83.02% | 65.29% | 223.89% | -228.6% | 111.52% | -298.93% | 1534.92% | -94.06% | -13.79% | 13.79% | 14.64% | 89.26% | -44.42% | 18.36% | 15.84% | 1.52% | -7.54% | 1.36% | -25.54% | 3.52% | -23.53% | 6.57% | 19.26% | 23.31% | 16.13% | 22.88% | 21.44% | 19.9% | 143.6% |
| EBITDA | 3.67B | 3.57B | 3.06B | 1.95B | 1.44B | 85M | 1.25B | -3.19B | 3.06B | 1.16B | 2.84B | 3.1B | 2.61B | 2.34B | 1.39B | 2.12B | 1.83B | 1.56B | 1.51B | 1.61B | 1.7B | 2.14B | 2.08B | 2.62B | 2.45B | 2.08B | 1.77B | 1.54B | 1.28B | 1.08B | 924.8M |
| EBITDA Margin % | 1.42% | 1.4% | 1.38% | 0.86% | 0.7% | 0.05% | 0.77% | -2.08% | 2.1% | 0.85% | 2.18% | 2.55% | 2.55% | 2.57% | 1.38% | 1.97% | 1.78% | 1.58% | 1.58% | 1.84% | 1.95% | 2.69% | 2.86% | 4.06% | 4.32% | 4.06% | 3.69% | 4.01% | 5.1% | 5.11% | 5.03% |
| EBITDA Growth % | 14.05% | 16.44% | 56.94% | 35.25% | 1598.82% | -93.23% | 139.4% | -204.08% | 164.25% | -59.18% | -8.48% | 18.68% | 11.43% | 68.27% | -34.2% | 15.87% | 17.04% | 3.16% | -6.15% | -4.92% | -20.85% | 3.11% | -20.7% | 6.82% | 18.08% | 17.51% | 14.97% | 20.09% | 18.93% | 16.4% | 177.47% |
| D&A (Non-Cash Add-back) | 970M | 956M | 790M | 710M | 692M | 692M | 783M | 913M | 1B | 1.03B | 717M | 641M | 451M | 459M | 397M | 325M | 313M | 254M | 225.8M | 220M | 322.1M | 297.6M | 295.6M | 289.5M | 265.8M | 243.5M | 280.6M | 257M | 238.2M | 218.4M | 209.1M |
| EBIT | 2.6B | 2.52B | 2.32B | 1.25B | 747M | -637M | 503M | -3.53B | 2.04B | 101M | 2.13B | 2.45B | 2.11B | 1.93B | 1.01B | 1.79B | 1.61B | 1.32B | 1.41B | 1.44B | 1.52B | 1.92B | 1.91B | 2.41B | 2.33B | 1.97B | 1.49B | 1.28B | 1.04B | 858.1M | 715.7M |
| Net Interest Income | -341M | -348M | -215M | -51M | -84M | -147M | -180M | -238M | -294M | -329M | -201M | -178M | -141M | -133M | -123M | -95M | -93M | -113M | -114.4M | -136.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 341M | 348M | 215M | 51M | 84M | 147M | 180M | 238M | 294M | 329M | 201M | 178M | 141M | 133M | 123M | 95M | 93M | 113M | 218.7M | 136.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -434M | -439M | -174M | -42M | -89M | -177M | -149M | 326M | -309M | -354M | -196M | -183M | -194M | -87M | -108M | -94M | 4M | -95M | -127.6M | -97.3M | -121.4M | -104.5M | -117.8M | -106.8M | -106.3M | -132.5M | -154.9M | -138.7M | -256.8M | -166.7M | -176M |
| Pretax Income | 2.26B | 2.17B | 2.1B | 1.2B | 663M | -784M | 323M | -3.77B | 1.75B | -228M | 1.92B | 2.28B | 1.97B | 1.8B | 888M | 1.7B | 1.52B | 1.21B | 1.67B | 1.95B | 1.25B | 1.83B | 1.63B | 2.24B | 2.13B | 1.7B | 1.33B | 1.08B | 759.2M | 402.5M | 312.3M |
| Pretax Margin % | 0.88% | 0.86% | 0.94% | 0.53% | 0.32% | -0.43% | 0.2% | -2.47% | 1.2% | -0.17% | 1.48% | 1.87% | 1.92% | 1.97% | 0.88% | 1.58% | 1.48% | 1.23% | 1.74% | 2.23% | 1.44% | 2.3% | 2.24% | 3.47% | 3.75% | 3.33% | 2.78% | 2.81% | 3.02% | 1.91% | 1.7% |
| Income Tax | 457M | 469M | 532M | 348M | 332M | 153M | -289M | -79M | 386M | -487M | 630M | 845M | 755M | 635M | 553M | 628M | 552.1M | 624.6M | 524.2M | 633.9M | 412.6M | 577.1M | 586M | 706.7M | 699.5M | 575M | 474.8M | 424M | 302.9M | 242.9M | 204.9M |
| Effective Tax Rate % | 20.19% | 21.57% | 25.32% | 28.98% | 50.08% | -19.52% | -89.47% | 2.09% | 22.04% | 213.6% | 32.74% | 37.13% | 38.38% | 35.32% | 62.27% | 36.98% | 36.36% | 51.55% | 31.45% | 32.51% | 32.95% | 31.45% | 35.97% | 31.57% | 32.89% | 33.8% | 35.64% | 39.34% | 39.9% | 60.35% | 65.61% |
| Net Income | 1.82B | 1.71B | 1.56B | 852M | 330M | -938M | 611M | -3.69B | 1.36B | 256M | 1.29B | 1.43B | 1.22B | 1.17B | 334M | 1.07B | 959M | 642.2M | 1.15B | 1.3B | 1.93B | 1B | 1.05B | 1.47B | 1.41B | 1.06B | 857.4M | 679.7M | 456.3M | 247.1M | 181.1M |
| Net Margin % | 0.71% | 0.67% | 0.7% | 0.38% | 0.16% | -0.52% | 0.38% | -2.42% | 0.94% | 0.19% | 0.99% | 1.17% | 1.19% | 1.28% | 0.33% | 0.99% | 0.93% | 0.65% | 1.2% | 1.49% | 2.22% | 1.26% | 1.45% | 2.29% | 2.48% | 2.07% | 1.79% | 1.77% | 1.82% | 1.17% | 0.98% |
| Net Income Growth % | 13.98% | 9.8% | 83.22% | 158.18% | 135.18% | -253.52% | 116.54% | -370.95% | 432.42% | -80.12% | -9.74% | 17.45% | 4.2% | 249.1% | -68.76% | 11.47% | 49.33% | -44.23% | -11.46% | -32.65% | 93.09% | -4.82% | -28.74% | 4.89% | 33.1% | 23.19% | 26.14% | 48.96% | 84.66% | 36.44% | 61.84% |
| Net Income (Continuing) | 1.81B | 1.71B | 1.57B | 853M | 331M | -937M | 612M | -3.69B | 1.36B | 259M | 1.29B | 1.43B | 1.21B | 1.16B | 335M | 1.07B | 966M | 587M | 758.2M | 847.2M | 839.7M | 1.16B | 1.07B | 1.52B | 1.38B | 1.13B | 857.4M | 717.8M | 481M | 448.5M | 334.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3M | 3M | 0 | 0 | 0 | 0 | 8.8M | -15.3M | 1.09B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 159M | 159M | 147M | 1M | 1M | 3M | 3M | 3M | 2M | 0 | 20M | 17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 7.80 | 7.23 | 6.45 | 3.45 | 1.26 | -3.34 | 2.08 | -12.60 | 4.53 | 0.81 | 4.03 | 4.32 | 3.62 | 3.38 | 0.97 | 3.06 | 2.72 | 1.77 | 3.18 | 3.57 | 4.77 | 2.33 | 2.41 | 3.35 | 3.03 | 2.33 | 1.85 | 1.58 | 1.12 | 1.02 | 0.82 |
| EPS Growth % | 16.59% | 12.09% | 86.96% | 173.81% | 137.72% | -260.58% | 116.51% | -378.15% | 459.26% | -79.9% | -6.71% | 19.34% | 7.1% | 248.45% | -68.3% | 12.5% | 53.67% | -44.34% | -10.92% | -25.16% | 104.72% | -3.32% | -28.06% | 10.56% | 30.04% | 25.95% | 17.09% | 41.07% | 9.8% | 24.39% | 60.78% |
| EPS (Basic) | - | 7.27 | 6.48 | 3.48 | 1.26 | -3.34 | 2.09 | -12.60 | 4.54 | 0.82 | 4.06 | 4.36 | 3.66 | 3.42 | 0.98 | 3.10 | 2.75 | 1.79 | 3.22 | 3.63 | 4.89 | 2.38 | 2.44 | 3.39 | 3.08 | 2.37 | 1.90 | 1.61 | 1.15 | 1.05 | 0.84 |
| Diluted Shares Outstanding | 233M | 237M | 242M | 247M | 262M | 279M | 294M | 293M | 301M | 315M | 320M | 330M | 335M | 345M | 344M | 349M | 352.5M | 361.4M | 361.5M | 364M | 404.7M | 428.5M | 435.98M | 429.91M | 453.83M | 453.3M | 463.46M | 454.3M | 427.8M | 416.85M | 238.4M |
| Basic Shares Outstanding | 232M | 236M | 241M | 245M | 261M | 279M | 292M | 293M | 300M | 313M | 317M | 327M | 332M | 341M | 341M | 345M | 348.6M | 358.8M | 357.6M | 358.2M | 394.9M | 421.2M | 430.61M | 424.84M | 446.46M | 445.65M | 451.26M | 445.84M | 416.55M | 406.8M | 233.73M |
| Dividend Payout Ratio | - | 28.65% | 31.65% | 58.57% | 159.09% | - | 93.78% | - | 42.33% | 226.95% | 44.8% | 35.88% | 37.86% | 35.59% | 105.69% | 28.06% | 28.59% | 39.41% | 17.4% | 13.31% | 7.48% | 10.18% | 4.92% | 3.55% | 3.19% | 4.26% | 4.27% | 4.41% | 12.43% | 4.65% | 5.02% |
Quick answers to the most common questions about buying CAH stock.
For fiscal year 2026, Cardinal Health, Inc. (CAH) reported total revenue of $254.25B. This represents a 1282.2% increase compared to $18.39B in 1997.
Cardinal Health, Inc. (CAH) is profitable, generating $1.71B in net income for the fiscal year ending 2026 with a net profit margin of 0.7%.
Cardinal Health, Inc. (CAH) reported an operating income of $2.61B, resulting in an operating profit margin of 1.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Cardinal Health, Inc. (CAH) generated $9.77B in gross profit for the year, representing a gross profit margin of 3.8%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Thin margins amplify volatility
Metrics are mathematically derived from official filings.
Volatile Growth Masks Flat Underlying Momentum
According to the reported quarterly income statements, CAH's revenue has swung between roughly negative 4% and positive 22% year over year across the last ten quarters, indicating growth that is highly sensitive to timing and volume shifts rather than a steady compounding trend.
The quarterly series shows revenue moving from $52.3B to $67.5B, with the strongest prints clustered in fiscal 2026 after several quarters of near-zero or negative growth. This pattern suggests the recent acceleration may reflect a recovery in pharmaceutical volumes and pricing rather than a durable step-change, so investors should monitor whether sequential revenue gains hold through the next two quarters. The trailing growth figure of roughly 299% in the snapshot appears distorted by a weak base and should not be extrapolated.
Razor-Thin Gross Margins Structurally Capped
Based on reported figures, CAH's gross margin has held in a narrow 3.1% to 4.3% band across the ten quarters, confirming a distribution model where cost of products sold consumes roughly 96% of revenue and pricing power is limited.
The stability of the gross margin band suggests that CAH has not materially expanded its spread despite growing scale, which is consistent with a high-volume intermediary role. Gross profit dollars have grown from about $1.9B to $2.6B, but this appears driven by volume rather than margin improvement. Any shift in generic deflation or manufacturer rebate timing would likely move the margin band directly, warranting continued scrutiny.
Modest Operating Leverage Emerging Recently
As reported in the quarterly statements, operating income rose from $408M to $753M while SG&A stayed near $1.2B to $1.6B, suggesting some operating leverage has begun to appear in the most recent periods.
Operating margin improved from about 0.7% to 1.1%, indicating that overhead growth has lagged gross profit growth in fiscal 2026. However, the absolute improvement is small relative to revenue scale, so the leverage appears modest and sensitive to a single quarter. Investors should treat this as an early signal requiring confirmation over multiple periods rather than a proven efficiency gain.
Net Income Lags Operating Gains Persistently
Based on EPS and net income figures, CAH's net margin of 0.4% to 0.9% sits well below its operating margin, and quarterly EPS swings from $0.96 to $2.38 point to meaningful non-operating or tax-related variability.
The gap between operating income and net income in several quarters, such as 2025Q3 where operating income was $730M and net income $506M, suggests interest, tax, or other non-operating items absorb a significant share of operating profit. Stock-based compensation of $30M to $153M per quarter is modest relative to earnings but should be considered alongside any one-time items. The EPS growth figures, including swings of 96% and negative 19.5%, appear to reflect this noise more than underlying earnings power.
Cost of Products Sold Dominates Entire Structure
According to reported figures, cost of products sold consumed roughly 96% of revenue in every quarter, leaving SG&A at about 2.4% to 2.9% of revenue as the only meaningful discretionary cost line.
With R&D reported as zero, the cost base is effectively a binary between product cost and overhead, implying that the company's profitability depends almost entirely on procurement spreads and distribution efficiency. SG&A has grown in dollar terms but has remained a stable share of revenue, which suggests reasonable expense discipline. Monitoring whether SG&A growth stays below revenue growth will be the key test of cost control going forward.
Thin Spreads Leave Little Margin for Error
As reported in the quarterly figures, CAH's net margin of roughly 0.4% to 0.9% leaves minimal buffer, so modest reimbursement pressure or cost inflation could erase recent earnings gains and expose the fiscal 2026 trajectory as partly cyclical.
A bearish reading would argue that the strongest quarters rely on favorable timing, tariff-related recoveries, or rebate movements rather than sustained spread expansion, and that the trailing 299% growth figure reflects a depressed base rather than durable momentum. The company's reported net income of $239M in 2025Q4 against $506M in 2025Q3 illustrates how quickly profitability can swing. Investors should therefore weigh management's constructive tone against the arithmetic of a sub-1% net margin business.